01 May OmniaBio

OmniaBio Inc. provides specialized, focused, cGMP-compliant CDMO services for cell and gene therapy (CGT) developers from pre-clinical through to commercial stage. As a CCRM subsidiary, OmniaBio is building on an established reputation in CGT manufacturing from a team and legacy that has been built over a decade. With leadership in iPSCs, immunotherapy and LVVs, OmniaBio provides a continuum of advanced process and analytical development, and manufacturing capabilities. OmniaBio’s flagship facility is located at McMaster Innovation Park in Hamilton, Ontario, Canada, and is a one-hour drive from the U.S. border. The two OmniaBio biomanufacturing plants are opening in a scaled launch between 2024 and 2026 and will total 400,000 sq ft of space featuring 47 clean rooms. This adds to the existing 40,000 sq ft of process development and cGMP space at the Toronto site, which features 10 GMP clean rooms for production of CGT products. www.omniabio.com